-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US81749D1072 |
| Sector | Healthcare |
| Industry | Medical Devices |
| PE Ratio | None |
|---|---|
| Target Price | 2.75 |
| Market Cap | 110M |
| Beta | 1.0 |
| Dividend Yield | None |
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for SERA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025